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analyses.9 The widespread focus on the signalling 
pathways to account for the modulation of physiologi-
cal changes and the commencement of pathological 
derivation10,11 has, to a certain degree, caused us to 
lose some fundamental perspective. The processes 
at the molecular level never occur in an ‘ideal’ iso-
lated setting, but are intricately involved in multiple 
metabolically and structurally complex systems, i.e. 
in cells which communicate with other cells within 
the same tissue, organ or at a systemic inter-organ 
level. There are several layers of superimposed (and 
completely intergraded) regulatory systems which 
contain fail-safe mechanisms to prevent catastrophic 
events in order to efficiently maintain life.
When we analyse the MS from a strictly physi-
opathological point of view, the most striking effects 
observed are those defined in the deadly quartet: 
obesity, hypertension, insulin resistance and hyperlipi-
demia.12 However, in this context, the term obesity is 
often further defined as upper body or visceral obesity.13 
This is an important point. Many obese women show a 
fairly normal metabolism, lacking a full manifestation 
of the MS,14,15 but in a high proportion of men, visceral 
obesity, even of limited extent, is often accompanied by 
the full manifestation of the MS associated diseases.16 
There is obviously a significant number of obese in-
dividuals who simply store more fat in their bodies 
without significant inflammation, insulin resistance, 
hypertension etc.;15,17 this type of obesity may reach 
high proportions of body fat, but it is often deposed 
in a lower body fat deposition (largely subcutane-
sexual dImoRphIsm In the metabolIc 
syndRome
The clairvoyant early implication of sex hormones 
in the characterization of the metabolic syndrome 
(MS) was detected early,1 and in accordance with the 
well-known sex-related main patterns of fat deposition 
in obesity: gynoid and android.2 The differences point 
to a direct implication of androgens and estrogens 
in the development, properties and maintenance of 
obesity and, by extension, to the cumulus of diseases 
grouped in the MS.3,4 For a long time, the key issue 
of the MS, i.e. the metabolic event explaining (and 
justifying) most of the derangements of the MS, has 
been considered to be insulin resistance.5,6 Later, the 
emphasis was directed to a lower molecular level, the 
inflammatory response of tissues, mainly white adipose 
tissue (WAT);7 this response was assumed to be me-
diated principally by cytokines.8 Currently, however, 
the number of research fronts open is considerable, 
with the emphasis on mechanistic molecular-level 
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ous) pattern.17 In contrast, android obesity is more 
harmful, even with markedly lower proportions of 
body fat.18 It is obvious that fat storage alone cannot 
constitute the basis of the MS pathology.19 Indeed, 
the reverse is true, since there are individuals with all 
the symptoms of a developed MS who show a body fat 
content within normalcy and who are oxymoronically 
defined as normal-weight obese.20,21
In general, women tend to show a dispersed dis-
tribution of fat most of which is located in the sub-
cutaneous space, whereas in men a large part of the 
fat is concentrated within the abdominal cavity.22 
In rodents, the differences are less marked, since a 
considerable amount of fat is stored in the abdominal 
space in the retroperitoneal and perigonadal pads, 
which cannot be equated with the omental fat of 
humans;23 it is hypothesized that rat mesenteric fat is 
closer in pathogenic potential and metabolic activity 
to human visceral fat.24
In any case, we should distinguish two main types of 
obesity, android and gynoid, based on the distribution 
of fat, the overall metabolic transcendence of excess 
fat and the severity of its health consequences. The 
implication of steroid hormones characterizes this 
large difference.25,26 There is a high degree of super-
position between the two main types of fat distribu-
tion, but in most cases the consequences can easily be 
derived from changes in sex hormone availability.27
Estrogens tend to limit body fat deposition,28,29 
and when there is ample fat storage under their 
aegis, its distribution adopts the gynoid pattern.30,31 
At menopause, when estrogen synthesis and levels 
sharply decrease, a redistribution of body fat occurs, 
diffusing the contours of the gynoid pattern towards a 
hybrid android-influenced pattern.32 This change has 
been attributed to a shift in the imbalance between 
androgens and estrogens.33
Androgens facilitate muscle and bone growth and 
maintenance34,35 and are also assumed to promote 
the male-related android distribution of body fat.36 
However, testosterone diminishes the accumulation 
of intra-abdominal fat.37 In fact, visceral fat is a major 
site for androgen inactivation,38,39 thus the fight is 
two-sided. In the MS, testosterone administration 
tends to lower body fat,40 and hypoandrogenism41 or 
androgen deprivation treatments are correlated with 
marked increases in fat deposition, both visceral and 
subcutaneous.42 
Hypoandrogenism (i.e. low levels of serum tes-
tosterone) is a common finding in the MS,41,43 usu-
ally paired with decreased dehydroepiandrosterone 
(DHEA) levels44 and lower synthesis/levels of andros-
tenedione and testosterone.45,46 Serum testosterone 
activity may be even lower because of its binding to 
SHBG 47,48 (sex hormone-binding globulin) and other 
testosterone-binding proteins,49 including CBG50 
(glucocorticoid-binding globulin). The generalized 
hypoandrogenemia observed in male obesity51 is com-
pounded by an increased aromatization of androgens 
to estrogens, especially in the enlarged adipose tissue52 
of the obese individual, producing estrogens53 and 
thus inducing estrogenization. Obesity favours this 
decrease in androgens by activation of the expression 
of aromatase,54 which adds to the large mass of adipose 
tissue, but also because of the targeted destruction of 
androgens.38,39,50 Inhibition of aromatase in obese men 
helps reverse their altered hypothalamus-pituitary-
gonadal axis towards androgen normalization.55
steRoIds and ms
Role of androgens in the pathophysiology of MS
Our blueprint for development sets the timing for 
the establishment of a number of changes in body 
function, shape and patterns of activity and behaviour 
inherited from our ancestors. The sex-related differ-
ences in fat distribution have a strong behavioural and 
sexual component; they have been well described for 
groups of gorillas,56 but are also—in part—applicable 
to humans. These changes (body shaping, baldness 
and/or graying hair in males) occur slowly, following a 
gene-controlled pattern 57 over a prolonged period of 
time, at specific points of the life-cycle and parallel to 
sex hormone synthesis (and levels).58,59 The process is 
controlled by the brain, mainly through hypothalamic 
control of gonadotropin secretion by the hypophysis, 
which regulates androgen and estrogen levels and 
follows precisely established developmental pat-
terns based on genetics60 and seasonal and circadian 
rhythmicities.61 The timing and extent of changes are 
also regulated by energy availability (e.g. by leptin 
secretion by WAT stores62,63) and other environmental 
factors (e.g. through cortical signals, glucocorticoids, 
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else in all physiological mechanisms.
Role of estrogens in the pathophysiology of MS
To produce estrogens we need first to synthesize 
androgens, starting with dehydroepiandrosterone; the 
last step being aromatization100,101 (Figure 1). Thus, 
the decline of DHEA caused MS may in the end 
diminish the estrogen-mediated beneficial effect on 
vascular endothelium integrity102 and defence against 
superoxidation.103 Estrogens also ameliorate insulin 
resistance104 and facilitate the handling of low-density 
lipoproteins by the liver.105,106 Estrogens play a protec-
tive role in the brain,107,108 the vascular tree109,110 and 
indeed in most other tissues, which is compatible with 
their profound effects on fat metabolism.111,112 The 
decline of estrogen levels following menopause113 
results in a rapid weakening of these protective roles, 
altering the equilibrium with androgens, especially in 
individuals not on estrogen-replacement therapies.114 
This is not akin to androgenization, since the decline of 
estrogens is followed by a fall in androgens. Estrogen 
replacement therapy may indeed deepen the deficit 
of androgens115 by stimulating shared inactivation 
paths. However, the loss of sex steroids equilibrium 
seems to be mainly an imbalance of both androgens 
and estrogens against corticosteroids. The decline 
in estrogen levels may well be the result of the loss 
of androgens.113
The ponderostat hypothesis
Estrone is a powerful anabolic hormone, promoting 
growth and the deposition of fat in the young,116 but 
is a fairly inactive estrogen.117 Estrone is synthesized 
in significant amounts by WAT,100,118 which stores it 
largely as its oleoyl-ester,119,120 a precursor of a pos-
tulated ponderostat signal.121
The ponderostat system (Figure 2) regulates lipid 
storage to an optimally adjusted mass, but the MS 
rapidly alters the pre-established ponderostat settings 
in such a way that either the brain becomes less sensi-
tive to the signal(s) from WAT or this tissue shows 
a decreased capability to synthesize the signalling 
molecule(s). In any case, we may say that in obesity, 
the brain has lost its ability to control the size of 
WAT,122 probably because of inadequate sensing of 
adipose tissue actual size due to either lower levels 
or insensitivity to ponderostat signals. The case of the 
active form of oleoyl-estrone is paradigmatic, since 
etc). Nevertheless, they always result in long or very 
long-term changes following the evolutionary blueprint 
for reproductive effectiveness and group survival.
The implication of estrogens and androgens in 
the development of the diseases associated with the 
MS was recognized very early, even before the term 
inflammation was applied in this context.31 A telltale 
sign of their implication is the growing incidence 
of the polycystic ovary syndrome,64 largely due to 
an alteration in androstenedione metabolism,65 but 
characterized by insulin resistance,66 low adiponectin67 
and a number of MS-related pathological traits.68-70 
Polycystic ovary syndrome is a component of the 
MS.71,72 Central to polycystic ovarian syndrome is an 
altered metabolism of androgens.73-75 Polycystic ovary 
syndrome is usually treated with metformin,76 an 
insulin sensitizer not affecting androgen metabolism.
It has been established that the different patho-
logical traits of the MS are present with varying 
intensity in different individuals, with predominance 
of diabetes, atherosclerosis, obesity, etc., often with 
non-pathological degrees of some of the diseases of the 
syndrome, although in some cases the full spectrum of 
diseases is evident. Polycystic ovary syndrome may be 
one such MS manifestation,72 this hypothesis largely 
based on its superimposed symptoms.77-79 It should 
be noted here that MS affects not only the female 
reproductive system but also the male. Indeed, MS 
in males causes hypoandrogenism,41,80 with decreased 
testosterone81,82 as well as adrenal weak androgen 
dehydroepiandrosterone DHEA levels.83,84 Thus, in 
both sexes the MS is associated with altered androgen 
metabolism.80,85-87
The imbalance between lower androgens and 
raised corticosteroids signals a permanent shift in 
metabolic priorities: androgens are highly anabolic, 
increasing protein preservation and skeletal (mus-
cle, bone) growth,88-90 whilst glucocorticoids pro-
mote protein degradation (to fuel gluconeogenesis, 
thus maintaining euglycemia) and induce skeletal 
regression, including loss of minerals from bone 
and generalized wasting.91-93 Androgens are natural 
antidepressants,94-96 and excess of glucocorticoids is 
associated with depression,97-99 another example of 
the antagonistic roles these steroid hormones play, 
at least in the brain, which in fact controls everything 
Figure 2. Schematic representation of the ponderostat model. The “ponderostat signal” is released into the bloodstream proportion-
ally to the mass of energy stored in adipose tissue. The brain recognizes its level and associates it to age, sex and energy availability. If 
the amount of fat reserves is inadequate, the brain can increase the availability of substrates largely through control of appetite (and 
thus food intake) and the action of the autonomous nervous system. A perceived lack of energy increases food intake and the secre-
tion of insulin, resulting in an overall increase in energy storage in adipose tissue. Conversely, perceived excess energy stored in adi-
pose tissue elicits a decrease in food intake, but also a sympathetic response, increasing lipolysis. In this manner, a larger proportion 
of available energy substrates is endogenous and may be used by brown adipose tissue (and other organs/tissues) for thermogenesis 
and its final elimination as heat.
Figure 1. Metabolism of steroid hormones. Relationships between the main glucocorticoids, androgens and estrogens.
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most of the damages caused by the MS are decreased 
or minimized by the pharmacological administration 
of this oleoyl-estrone, derivative and postulated pre-
cursor of a ponderostat signal.123
Ponderostat settings are subjected to the changes 
in body weight reserves pre-established by our genes, 
epigenetic modulations and developmental influences, 
and shift throughout our entire life. One of the most 
dangerous effects of the MS is precisely the changes it 
induces in our ponderostat settings. Obese individuals 
encounter all types of physiological difficulties when 
trying to lose weight124-126 largely because their ill-
adjusted ponderostat setting is defended by the body 
mechanisms that prevent the loss of its reserves. Our 
lack of knowledge on how the ponderostat sequence of 
events works and how it is set up makes us uncertain 
as to the importance of this mechanism with regard 
to MS manifestations.127 Glucocorticoids may play a 
role in the maladjustment of the ponderostat setting, 
both because of their omnipresence in the MS128-130 
and their role, as yet little known, in the control of 
androgen and estrogen metabolism,131-134 which may 
extend to its counteracting effects upon the estrone-
derived ponderostat signal candidate.135
Role of glucocorticoids in the pathophysiology 
of MS
It is clear that androgens and estrogens cannot 
alone account for the ravages and, especially, the 
timing of appearance of the associated pathologies 
of the MS. However, there is a third and critical ele-
ment in the equation: corticosteroids, and mainly 
glucocorticoids. The implication of glucocorticoids 
in obesity are well known.136-138 Specifically, the main 
enzyme converting cortisone (less active) and cortisol 
(active),	type	1	11β-hydroxysteroid	dehydrogenase,	
is present and functional in WAT139,140 (Figure 1). 
This allows adipose tissue to generate active cortisol 
from circulating less active cortisone.141,142 Cortisol is 
essentially the product of the cortex of the adrenal 
glands, which also produce aldosterone,143 dehydroepi-
androsterone (DHEA)144 and lesser amounts of sex 
hormones.145 Glucocorticoids play a crucial role in 
the control of homoeostatic stability: they induce 
resistance to insulin146,147 and other hormones and 
cytokines135,148 (including glucocorticoids themselves149) 
and enhancement of liver gluconeogenesis,150 largely 
at the expense of body protein;151 they also mobilize 
minerals from the bone,152 hamper the full immune 
response to real (or feigned) aggressions,153 favour 
lipid deposition147 and help the body to recover after 
any physical exertion or stressful situation (exercise, 
exhaustion, infection, stress, etc.).154,155 These roles 
are critical for survival and thus take precedence over 
the more slow effects of sex hormones, which effects 
become more extended over time.156 The immediacy 
of glucocorticoid action, however, is not absolute, 
especially when we compare it with actions as fast 
as these of catecholamines whose effects start in the 
split-second range (i.e. fight-or-flight situations);157 
glucocorticoids act at a slower pace, but neverthe-
less much faster than the longer periods needed for 
many of the actions of estrogen and androgen to 
manifest.158,159
In the MS, the hypothalamus-pituitary-adrenals 
axis is more active than under normal conditions160 
and there is a close relationship between obesity 
and stress.161,162 However, the circulating levels of 
cortisol in MS are often within the normal range,163 
since part of the modulation of corticosteroid action 
depends on the peripheral conversion (i.e. within the 
same target tissue) of cortisone and of the less active 
cortisone.164,165 There is also a complex control of 
hormone availability through variability of both its 
transport in blood compartments and attachment to 
cells largely through CBG.166,167
An additional third level of regulation arises from 
the formation of dimeric structures by steroid hormone 
receptors,168,169 which enables the chimeric formation 
of hybrids of glucocorticoid-bound receptors with 
other ligands such as androgens,170 estrogens171 and 
retinoids.172
Glucocorticoids inhibit the synthesis and activity 
of androgens.173-175 However, androgen precursor 
DHEA (and, consequently, precursor of estrogens176) 
has anti-glucocorticoid activity.177,178 Glucocorticoids 
may hamper the activity of estrogens. 179 It should be 
noted here that activation of the estrogen receptor 
affects the brain glucocorticoid receptor-dependent 
effects in the amygdala and in the neuroendocrine 
system are opposed.180 However, glucocorticoids and 
estrogens may also act synergistically. Indeed, estro-
gens and glucocorticoids inhibit endothelial vascular 
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cell adhesion molecule-1 expression and suppress 
vascular endothelial inflammation.181,182 
The glucocorticoid relationship with androgens is 
perhaps more antagonistic because of their different 
effects at the cellular level: androgens as enhancers 
of protein synthesis are powerful anabolic agents,183 
and corticosteroids tend to mobilize protein184,185 to 
reap enough gluconeogenic substrates for the main-
tenance of glycemia.186 Excess glucocorticoids (often 
at pharmacologic levels) induce protein, glycogen 
and mineral wasting.92
In the climacteric transition, women’s synthesis 
of estrogen decreases187 and a few androgenic effects 
appear, such as the redistribution of body fat188,189 and 
weight increase190 as well as the loss of most of the 
protective effects of estrogen on the brain, skin and 
cardio-circulatory systems.191,192 There is a relative 
increase in androgens at menopause,193,194 but glucocor-
ticoid activity is also increased.195 The transformation 
in body fat redistribution and increased deposition 
during menopause appears to be a consequence of 
a transient androgen increase and a slow but steady 
rise of the circulating glucocorticoids. 
One of the main health problems associated with 
menopause, bone demineralization,197 is a telltale in-
dicator of both low estrogens and high corticosteroids, 
especially the latter. In males, this demineralization 
occurs at a slower pace, even in obese individuals 
with low levels of circulating testosterone.198 It seems 
that even low androgen levels may be sufficient to 
prevent or limit osteoporosis. Consequently, it is 
not logical to attribute the change of gynoid to an-
droid (or intermediates) fat distribution patterns at 
menopause to androgenization. If there were indeed 
sustained androgen activity increases, the bone may 
be effectively protected as in men. Meanwhile, the 
conversion of androgens to estrogens, albeit limited, 
should help further protect bone minerals. The effects 
observed in post-menopausal women are not, thus, 
only attributable to an imbalance between estrogens 
and androgens but mainly between estrogens and 
glucocorticoids.
glucocoRtIcoIds, InflammatIon and ms
The deranged actuation of the immune system 
may also be at the root of a number of MS-related 
diseases such as psoriasis199,200 and other autoimmune 
pathologies.201 Probably, the excess proinflammatory 
cytokine production of inflamed cells induces an 
excessive stimulation of the defence system.202,203 The 
actual absence of real enemies of the immune system 
to efficiently fight, as well as the lack of coordination of 
the estrogen and glucocorticoid secretion and function, 
may enhance the levels and activity of the latter. The 
higher incidence of a few types of cancer (excluding 
those related to food consumption204) in obesity and 
the MS205,206 corroborate this interpretation.
The change in microbiota composition elicited by 
excess secretion of nitrite into the digestive system207 
may also combine with a strong and activated immune 
system208 to modify the intestinal interface with the 
microbial symbiotic biota.209 This question has barely 
been analysed, except for the verified differences in the 
species distribution of the microorganisms, confirming 
what is known about obese microbiota,210,211 which is 
fairly independent of the type of food consumed212 
and is very different from the normal microbiota in 
species distribution and proportions. The existence 
of low, albeit constant, levels of lipopolysaccharide in 
the blood of obese individuals213 suggests that a low-
level intensity microbial-induced inflammation may 
be a significant cause of the inflammatory response 
observed in the MS.214 However, there are other plau-
sible explanations, such as the great predominance of 
glucocorticoids, secreted in response of an enhanced 
immune system activity,153 acting on the control of the 
bacteria kept at bay in the intestine,215 or an excessive 
monocyte and macrophage phagocytic response to 
infection releasing residual lipopolysaccharide into 
the bloodstream.213
bRaIn pondeRostat settIngs and ms
The most elusive (and least known) effects of the 
MS occur in the brain; they can be arbitrarily divided 
into a number of superimposed actions:
a) modulation of the ponderostat size of body fat 
reserves (changes in ponderostat setting, modu-
lation of food intake and modulation of energy 
expenditure)
b) effects on rhythms, sleep and meal patterns
c) effects on thymic and reward circuits
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d) modulation of hormone secretion
e) changes in the pattern (blueprint) for the life-cycle
f) alterations of behaviour
Evidently, the modification of the ponderostat 
setting is a powerful tool for the epigenetic adapta-
tion to environments with low food availability, since 
a higher setting results in higher efficiency in food 
energy utilization and the storage of fat when the 
energy is available. This trait (thrifty phenotype216,217) 
is a direct cause of obesity under conditions of excess 
available food energy. However, the consumption of a 
very rich diet for a long time (e.g. cafeteria diet218,219) 
also disrupts the adjustment of the ponderostat and 
results in obesity220 without the epigenetic preparation 
for hard times ahead. It may be speculated that the 
ponderostat setting may be altered by metabolic or 
hormonal signals. It is difficult, however, to determine 
how, since we do not know for certain which is (are) 
the adipose tissue signal(s) that inform the brain of 
the mass of stored energy.
Obese persons retain a considerable ability to 
maintain their body weight,221,222 albeit in a high, non-
physiological setting. Hypocaloric diets have a limited 
effect in the obese223,224 because in the end the body 
tries to regain the preset mass of reserves225 and the 
ponderostat system forces the metabolic paths to save 
energy and store it to maintain the pre-established 
levels (ponderostat setting). The ponderostat works 
mainly by establishing an equilibrium between energy 
intake (appetite) and energy expenditure (comple-
mented by the modulation of thermogenesis)226 (Figure 
2). Appetite is largely controlled by the hypothalamus 
through two confronted systems: NPY as main food 
intake promoter227,228 and melanocortins as inhibi-
tors.229,230 Significantly, the precursor of melanocortins, 
proopiomelanortin, is also a precursor of endorphins 
and ACTH corticotrophin.231 Melanocortin signaling is 
also related to melanin deposition in the skin232 (it in-
tervenes in the development of acanthosis nigricans,233 
a complication of diabetes234). Melanocortin is closely 
functionally related to orexins235 which intervene in 
the establishment of the complex network control-
ling food intake.236 Orexins are also implicated in the 
regulation of sleep and sleep cycles.237
otheR aspects of the bRaIn – adIpose 
tIssue InteRactIon
There is a direct relationship between sleep and 
the development of the MS.238,239 Sleep deprivation 
induces MS-like disturbances;240,241 in general, obese 
individuals sleep less time than non-obese242,243 and 
the deleterious effects of sleep apnoea are not only 
the consequence of the catecholamine surges but 
mainly of the loss of sleep quality.244 The sleep changes 
observed in the MS are also related to the alteration 
in circadian feeding and activity rhythms found in 
obesity245 and which are largely regulated by ACTH 
corticotropin / corticosteroids.246 The loss of rhythms 
favours increased (unscheduled) food intake and the 
nibbling of food results in a disarranged meal feed-
ing structure,247 which adds to the behavioural and 
neurochemical alterations associated with the MS.
It is important to note that in a small area of 
the lower brain (hypothalamus and surrounding 
structures) a large part of the control of food intake 
is concentrated,248 including, most probably, the ad-
justment of the ponderostat setting, the control of 
thermogenesis, sleep and circadian rhythms and the 
regulation of the hypophysis, which in turn controls 
most of the endocrine axes that regulate the function 
of the thyroid, adrenals, gonads and the water, mineral 
and electrolyte equilibrium.249-251 These mechanisms 
should be considered together with the direct influ-
ence on the autonomous nervous system functions 
(control of digestive tract motility, thermoregulation, 
heart rate, arterial tension and hemodynamic changes, 
to cite a few).252-254
The centres controlling the nervous system mecha-
nisms of reward (dopamine, endorphins)255 are close 
to and in direct relation with the hypothalamus,256,257 
which is also under the more or less direct control of 
cortical (voluntary) and sensorial areas,258,258 includ-
ing interoceptors detecting the status of intestine 
replenishment (and the nature of its contents),259 
glycemia,260 blood acid-basic equilibrium, oxygen and 
osmotic pressure.261,262
Pharmacology gives us a number of possible clues 
to the function of the system. If cortical hedonic signals 
decrease by applying a pre-established hypocaloric 
diet, the increase of serotonin signalling helps reduce 
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body weight (dexfenfluramine, sibutramine)263,264 in 
a process akin to the treatment of depression (fluox-
etine, sertraline).265,266 Again, glucocorticoids counter 
these effects and induce depression,267 which may 
be counteracted by serotonergic stimulation.268 The 
implication of cannabinoid receptors269 (rimonabant 
is an inverse cannabinoid CB1receptor blocker270), 
and catecholamines (amphetamine inhibiting food 
intake271 and phentermine or ephedrine increasing 
energy expenditure272) shows that the mechanisms 
controlling food intake and energy output, i.e. the 
ponderostat-driven mechanisms to regulate body 
energy, are multiple, complex and intertwined.
There are a number of drugs that cause iatro-
genic obesity, including synthetic glucocorticoids,273 
adrenergic blockers274 and a number of drugs used 
for psychiatric disorders.275,276 The discontinuation of 
nicotine stimulation in smokers produces a significant 
increase in appetite and permanent weight gain277 and 
the improvement of a number of psychiatric condi-
tions results, again, in overweight.278 Sometimes it It 
is difficult to distinguish between iatrogenic effects 
and normalization, i.e. suppression of a continued 
non-physiologic stimulus such as nicotine.
Surprisingly, the relationship of the MS with eat-
ing disorders is less manifest. A number of obese 
individuals present the psychological characteristics 
of binge eating,279,280 but this may be a result of a co-
operative cause, overeating, that has brought them 
to obesity,281 scaled up to the MS as a consequence, 
not the other way around.282 This may also be a con-
sequence of unchecked stress that is compensated 
by comfort feeding.283,284
In sum, there is considerable evidence linking the 
different diseases and symptoms attributed to the MS, 
essentially in a web-like manner, resulting in the self-
maintenance of most pathological traits. The increased 
knowledge of pathogenic paths only tends to strengthen 
the conclusion of the existence of a powerful linkage 
between the MS components.10,285,286 Nevertheless, 
two major issues challenge this general view: a) the 
lack of identification of a hierarchical line-up of the 
diseases, with a clearly identifiable origin for the whole 
MS pathology tree and branches, and b) the extreme 
resilience of the system to therapeutic intervention.
conclusIons
The evidence linking the function of androgens, 
estrogens and glucocorticoids with the MS is abundant 
and consistent.287 
Glucocorticoids: The full development of the MS 
pathologies is enhanced by glucocorticoids. Glucocor-
ticoids suppress inflammation, a central characteristic 
of MS, and keep the immune system at bay. However, 
glucocorticoids provoke insulin and leptin resistance, 
which aggravates the already altered energy handling 
control of the MS, favouring fat synthesis, protein 
mobilization and increased liver glucose output. 
Glucocorticoids also alter the ponderostat setting, 
thus influencing the deposition of fat both through 
the loss of insulin control of glycemia, increased 
lipogenesis and energy availability and deregulation 
of the ponderostat system. 
Androgens, on the other hand, tend to protect 
body protein and maintain growth: they are probably 
major glucocorticoid antagonists. Patients with MS 
pathologies are prone to hypoandrogenism in parallel 
to hypercortisolism. 
Estrogens are critical for control of inflammation 
because of their protective and antioxidant proper-
ties. They are more potent than androgens when 
countering the combined effects of inflammation and 
glucocorticoids and are thus able to maintain a more 
robust resistance to the MS manifestations in females 
than that evident in males (Table 1). At menopause, 
however, the differences tend to disappear because 
of the fall in estrogen. 
In summary, the equilibrium maintained in condi-
tions of basal health conditions between androgen, 
estrogen and glucocorticoids are deeply altered by 
the dietary and environmental causes of the MS, es-
tablishing the preponderance of glucocorticoids over 
the other steroid hormone types as the main factor 
responsible for the appearance of its related patholo-
gies. The marked differences in MS manifestations 
between females and males and the increasing rates 
of appearance (and severity) with advancing age (and 
losses of androgen and estrogen) help reinforce this 
hypothesis.287
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